Drugs / THR-184
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT01830920 | May 2013 → Sep 2015 | acute kidney injury | Thrasos Innovation, Inc. | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | THR-184 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01830920 ↗ |
| Modality | Peptide | “THR-184 is a synthetic oligopeptide administered intravenously.” NCT01830920 ↗ |
| Route | Intravenous | “administered intravenously” NCT01830920 ↗ |